Kalshi is expanding its wagers to include bets on drug trial results, an expansion into new predictions territory as platforms continue to rapidly gain popularity and offer opportunities to bet on virtually anything.
The betting platform said the expansion into clinical trials and FDA regulatory decisions would help surface information on drug trials that otherwise go unreported. A publicly listed contract on a drug trial would produce a “continuously updated, public probability that reflects the weight of the evidence, rather than the preferred message of the trial sponsor”, the company said.
